Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer. It works by inhibiting DNA transcription and repairing processes, leading to the death of cancer cells [1]. According to the Mayo Clinic, common side effects of lurbinectedin include fatigue, nausea, vomiting, diarrhea, and loss of appetite. Other less common side effects include anemia, low white blood cell count, low platelet count, and liver toxicity [2].

As for long-term effects, there is limited information available. A study published in the Journal of Clinical Oncology reported that the most common adverse events in patients receiving lurbinectedin were hematologic and gastrointestinal, and there was no evidence of cumulative toxicity or delayed toxicity [3]. However, the study only followed patients for up to 6 months, so the long-term effects of lurbinectedin are still unknown.

In conclusion, lurbinectedin is a chemotherapy drug used to treat small cell lung cancer. While it has some common side effects, such as fatigue and nausea, there is limited information available about its long-term effects. A study published in the Journal of Clinical Oncology reported no evidence of cumulative or delayed toxicity, but the long-term effects of lurbinectedin are still unknown [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804
[3] https://pubmed.ncbi.nlm.nih.gov/32055920/